インデックス付き
- 学術雑誌データベース
- Jゲートを開く
- Genamics JournalSeek
- アカデミックキー
- ジャーナル目次
- 中国国家知識基盤 (CNKI)
- サイテファクター
- シマゴ
- ウルリッヒの定期刊行物ディレクトリ
- 電子ジャーナルライブラリ
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- OCLC-WorldCat
- SWBオンラインカタログ
- 仮想生物学図書館 (vifabio)
- パブロン
- ミアル
- 大学補助金委員会
- ジュネーブ医学教育研究財団
- ユーロパブ
- Google スカラー
このページをシェアする
ジャーナルチラシ
概要
Pharmacokinetic Comparison of Two Gabapentin Formulations in Healthy Volunteers
Wen Yao Mak, Siew Siew Tan, Jia Woei Wong, Siaw Kuen Chin, Ai Boey Lim, Ean Peng Soon, Irene Looi and Kah Hay Yuen
The objective of the study was to establish bioequivalence between a local generic against the innovator product of gabapentin 300 mg. The study design was a standard two-way crossover, open-label, randomised and single dose study in 24 healthy male volunteers under fasting condition. The washout period was 7 days between both periods to allow adequate drug elimination. Liquid chromatography tandem mass spectrometry was utilised to determine gabapentin concentration in plasma. Non-compartmental model was used to analyse Tmax, Cmax, AUC0-t, AUC0-∞, t1/2 and ke. Potential adverse events were closely monitored and recorded throughout the study. The study found all pharmacokinetic parameters were within the bioequivalence limit of 80.00%-125.00%, with minimum side effects. In conclusion, the generic product was bioequivalent to the innovator product.